Related Experiment Video

Updated: Mar 26, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Barriers And Motivators for Smoking Cessation in Patients With Systemic Lupus Erythematosus (SLE)

Deirdra R Terrell, Lauren M Stewart, Eleni L Tolma

    The Journal of the Oklahoma State Medical Association
    |January 29, 2016
    PubMed
    Abstract

    More Related Videos

    Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells09:15

    Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

    Published on: May 11, 2020

    6.6K
    Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System06:07

    Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

    Published on: October 22, 2020

    7.9K

    Related Concept Videos

    COPD: Management Using Bronchodilators and Corticosteroids01:26

    COPD: Management Using Bronchodilators and Corticosteroids

    Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
    1.1K
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    578
    Chronic Obstructive Pulmonary Disease-V: Management01:29

    Chronic Obstructive Pulmonary Disease-V: Management

    Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
    Smoking Cessation
    3.3K
    Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

    Chronic Obstructive Pulmonary Disease-V: Nursing Management

    Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
    Assessment
    5.4K
    Chronic Obstructive Pulmonary Disease01:24

    Chronic Obstructive Pulmonary Disease

    COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
    Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
    3.1K
    Antiasthma Drugs: Leukotriene Modifiers01:19

    Antiasthma Drugs: Leukotriene Modifiers

    Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
    Leukotriene modifiers work through two distinct mechanisms:
    2.2K